Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immatics ( (IMTX) ) just unveiled an update.
On December 11, 2025, Immatics announced updated results from its Phase 1a clinical trial of the IMA203CD8 PRAME cell therapy, which targets heavily pre-treated patients with solid tumors. The data, with a cutoff date of October 27, 2025, revealed that the therapy demonstrated manageable tolerability and promising anti-tumor activity, with a confirmed objective response rate of 36% and a disease control rate of 84% at week 6. The trial’s ongoing dose escalation aims to determine the recommended Phase 2 dose in 2026, potentially positioning IMA203CD8 in a tumor-agnostic setting beyond melanoma, particularly in gynecologic cancers. This development could enhance Immatics’ standing in the biopharmaceutical industry by expanding its therapeutic offerings across a broader spectrum of PRAME-expressing cancers.
The most recent analyst rating on (IMTX) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.
Spark’s Take on IMTX Stock
According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.
Immatics’ overall stock score is primarily influenced by its financial performance challenges, including inconsistent revenue growth and profitability. Positive technical indicators provide some support, suggesting potential short-term bullish momentum. However, the negative P/E ratio and lack of dividend yield highlight valuation concerns. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on IMTX stock, click here.
More about Immatics
Immatics N.V. is a clinical-stage biopharmaceutical company specializing in the precision targeting of PRAME, a cancer-testis antigen. The company focuses on developing cell therapies for treating solid tumors, with a particular emphasis on PRAME-expressing cancers.
Average Trading Volume: 803,362
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.35B
For a thorough assessment of IMTX stock, go to TipRanks’ Stock Analysis page.